Clinical combination therapy for IBD and promising co-delivery strategies

Area of Science:

• Gastroenterology
• Pharmacology
• Biotechnology

Background:

• Biological agents are primary treatments for inflammatory bowel disease (IBD), but 33% of patients show poor initial response or waning efficacy.
• Combination therapies (biological agents with immunomodulators or small molecules) enhance efficacy and combat resistance in IBD.
• Challenges in current IBD treatment include optimizing dosing and managing systemic toxicities.

Purpose of the Study:

• To review combination dosing strategies for inflammatory bowel disease (IBD).
• To examine nanodelivery methods for IBD treatment.
• To explore novel approaches for advancing nanodelivery technology in IBD combination therapies.

Main Methods:

• Review of existing literature on combination therapies for IBD.
• Analysis of nanocarrier systems (e.g., nanoparticles, liposomes, hydrogels) for drug delivery in IBD.
• Examination of clinical data on combination therapy efficacy and toxicity.

Main Results:

• Combination therapies like infliximab/azathioprine and triple therapy (vedolizumab/adalimumab/methotrexate) show significant improvements in remission and healing rates.
• Specific combinations (guselkumab/golimumab) demonstrate high response rates in ulcerative colitis.
• Nanocarrier research indicates enhanced anti-inflammatory effects, mucosal healing, and gut microbiota modulation for colitis treatment.

Conclusions:

• Nanocarriers offer a promising solution for IBD by enabling targeted delivery, simplifying treatment, and minimizing toxicity.
• Advanced delivery systems can improve anti-inflammatory effects and promote gut health in IBD.
• Further research into nanodelivery technology is crucial for advancing combination therapies in clinical practice.